Preoperative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 19, Issue 1, 2005, Pages 4-10

  McDonald, Susan B ^a   Renna, Maurizio ^a   Spitznagel Jr , Edward L ^a   Avidan, Michael ^a   Hogue Jr , Charles W ^a   Moon, Marc R ^b   Barzilai, Benico ^a   Saleem, Rao ^a   McDonald, Jerome M ^a   Despotis, George J ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bleeding; Complications; Heparin; Inhibitors; Platelets; Surgery

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN; WARFARIN;

ADULT; AGED; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEART SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 13844273744     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2004.11.002     Document Type: Article

References (46)

1. E. Deutsch The emerging role of low-molecular-weight heparin and antiplatelet therapies in the cardiac catheterization laboratory Am Heart J 138 1999 S577 S585
2. M. Cohen, C. Demers, E.P. Gurfinkel A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group N Engl J Med 337 1997 447 452
3. S. Kaul, P.K. Shah Low molecular weight heparin in acute coronary syndrome Evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 35 2000 1699 1712
4. A.M. Lincoff, L.A. LeNarz, G.J. Despotis Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing Ann Thorac Surg 70 2000 516 526
5. J.P. Zidar Rationale for low-molecular weight heparin in coronary stenting Am Heart J 134 1997 S81 S87
6. A.M. Lincoff, J.E. Tcheng, R.M. Califf Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One-year outcome in the EPILOG trial. Evaluation in PTCA to improve long-term outcome with abciximab GP IIb/IIIa blockade Circulation 99 1999 1951 1958
7. S.R. Steinhubl, S.G. Ellis, K. Wolski Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events Data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial Circulation 103 2001 1403 1409
8. F.A. Cura, D.L. Bhatt, A.M. Lincoff Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions Circulation 102 2000 28 34
9. B.E. Tardiff, R.M. Califf, J.E. Tcheng Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to minimize platelet aggregation and coronary thrombosis-II J Am Coll Cardiol 33 1999 88 96
10. L.J. Dacey, J.J. Munoz, Y.R. Baribeau Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors. Northern New England Cardiovascular Disease Study Group Arch Surg 133 1998 442 447
11. L.M. van de Watering, J. Hermans, J.G. Houbiers Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery A randomized clinical trial Circulation 97 1998 562 568
12. M.A. Mascelli, E.T. Lance, L. Damaraju Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade Circulation 97 1998 1680 1688
13. Y. Hiramatsu, N. Gikakis, H.L. Anderson III Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons J Thorac Cardiovasc Surg 113 1997 182 193
14. Y. Suzuki, P. Hillyer, S. Miyamoto Integrilin prevents prolonged bleeding times after cardiopulmonary bypass Ann Thorac Surg 66 1998 373 381
15. P.J. Sharis, C.P. Cannon, J. Loscalzo The antiplatelet effects of ticlopidine and clopidogrel Ann Intern Med 129 1998 394 405
16. L.R. Dolovich, J.S. Ginsberg, J.D. Douketis A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism examining some unanswered questions regarding location of treatment, product type, and dosing frequency Arch Intern Med 160 2000 181 188
17. B.E. Tardiff, J.E. Tcheng, S. Peck Bleeding with coronary artery bypass surgery (CABG) in patients treated with a platelet glycoprotein IIb/IIIa inhibitor J Am Coll Cardiol 29 1997 5212B 5212B
18. J.J. Young, D.J. Kereiakes, C.L. Grines Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators J Invasive Cardiol 12 suppl E 2000 E14 E18
19. J.S. Gammie, M. Zenati, R.L. Kormos Abciximab and excessive bleeding in patients undergoing emergency cardiac operations Ann Thorac Surg 65 1998 465 469
20. R.L. Bick Alterations of hemostasis associated with cardiopulmonary bypass Pathophysiology, prevention, diagnosis, and management Semin Thromb Hemost 3 1976 59 82
21. N.J. Skubas, G.J. Despotis, J.J. Vlasnic Preoperative use of enoxaparin and tirofiban possible association with increased bleeding postbypass Anesthesiology 91 1999 869 872
22. J.M. Alvarez Emergency coronary bypass grafting for failed percutaneous coronary artery stenting Increased costs and platelet transfusion requirements after the use of abciximab J Thorac Cardiovasc Surg 115 1998 472 473
23. S.C. Clark, N. Vitale, J. Zacharias Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery Ann Thorac Surg 69 2000 762 764
24. S. Massonnet-Castel, E. Pelissier, L. Bara Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate In vitro and in vivo study during cardiac surgery with extracorporeal circulation Haemostasis 16 1986 139 146
25. N. Gikakis, A.K. Rao, S. Miyamoto Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons J Thorac Cardiovasc Surg 116 1998 1043 1051
26. A.K. Ganjoo, M.G. Harloff, W.D. Johnson Cardiopulmonary bypass for heparin-induced thrombocytopenia: management with a heparin-bonded circuit and enoxaparin J Thorac Cardiovasc Surg 112 1996 1390 1392
27. E. Prifti, M. Bonacchi, M. Leacche Undergoing cardiopulmonary bypass using enoxaparin only during a cardiac transplantation procedure Eur J Cardiothorac Surg 17 2000 760 762
28. M.J. Moulton, L.L. Creswell, M.E. Mackey Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations J Thorac Cardiovasc Surg 111 1996 1037 1046
29. G.J. Despotis, S.A. Santoro, E. Spitznagel Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation J Thorac Cardiovasc Surg 107 1994 271 279
30. H.U. Jones, J.B. Muhlestein, K.W. Jones Preoperative use of enoxaparin compared to unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open heart surgery in patients who present with an acute coronary syndrome Clinical investigations and reports Circulation 106:12 suppl 1 2002 I19 I22
31. J.H. Lemmer Jr, M.T. Metzdorff, A.H. Krause Jr Emergency coronary artery bypass graft surgery in abciximab-treated patients Ann Thorac Surg 69 2000 90 95
32. S. Massonnet-Castel, E. Pelissier, G. Dreyfus Low-molecular-weight heparin in extracorporeal circulation Lancet 1 1984 1182 1183
33. O. Shigeta, H. Kojima, Y. Hiramatsu Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass J Thorac Cardiovasc Surg 118 1999 354 360
34. T. Ammar, C.F. Fisher The effects of heparinase 1 and protamine on platelet reactivity Anesthesiology 86 1997 1382 1386
35. R.J. Kohtz, C.M. Petterson, N.J. Mills Effects of ultrafiltration on enoxaparin an in vitro analysis J Extra Corpor Technol 33 2001 94 99
36. B.P. Schick, J.F. Gradowski, J.D. San Antonio Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans Thromb Haemost 85 2001 482 487
37. T.W. Wakefield, P.C. Andrews, S.K. Wrobleski A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation J Surg Res 63 1996 280 286
38. M. Levi, M.E. Cromheecke, E. de Jonge Pharmacological strategies to decrease excessive blood loss in cardiac surgery A meta-analysis of clinically relevant endpoints Lancet 354 1999 1940 1947
39. G.J. Despotis, V. Levine, R. Saleem Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery A randomised controlled trial Lancet 354 1999 106 110
40. M. Al Douri, T. Shafi, D. Al Khudairi Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery Blood Coagul Fibrinolysis 11 suppl 1 2000 S121 S127
41. T.T. Horlocker, J.A. Heit Low molecular weight heparin Biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management Anesth Analg 85 1997 874 885
42. W. Lewis, C.D. Collard Does perioperative antithrombotic therapy increase the likelihood of a postoperative coagulopathy after cardiac surgery? Anesthesiology 92 2000 1499 1501
43. Micromedex/Thompson Healthcare Enoxaparin Quebecor World 2001 1361 1364
44. J. Holst, B. Lindblad, D. Bergqvist Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers Blood Coagul Fibrinolysis 5 1994 795 803
45. J. Hajek A Course in Nonparametric Statistics 1969 Holden-Day San Francisco, CA pp 83-85
46. J.D. Boehrer, D.J. Kereiakes, F.I. Navetta Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation prevention of ischemic complications Am J Cardiol 74 1994 1166 1170